CD8A and neoplasm: This study utilized a high-throughput screening approach to serially interrogate CD8 T cell recognition of patient-specific neopeptides predicted from the pre-treatment tumor mutagenome in the peripheral blood of 24 patients with mUC treated with anti-PD-L1-therapy.